Allakos Inc. (ALLK) Stock Analysis

Allakos Inc. (ALLK) Healthcare & Pipeline Overview

Allakos Inc. is a clinical-stage biopharmaceutical company specializing in therapeutics for allergy, inflammatory, and proliferative diseases. Its lead product, lirentelimab (AK002), targets immunomodulatory receptors and is currently in Phase III trials for eosinophilic gastritis/duodenitis and Phase II/III trials for eosinophilic esophagitis, positioning the company within the competitive biotechnology landscape.

What Is the Investment Thesis for ALLK?

Allakos Inc. presents a high-risk, high-reward investment opportunity characteristic of clinical-stage biopharmaceutical companies. The primary value driver is the successful development and commercialization of lirentelimab (AK002). Positive results from the ongoing Phase III study for eosinophilic gastritis/duodenitis and the Phase II/III study for eosinophilic esophagitis are critical catalysts. A gross margin of 50.0% suggests potential profitability upon commercialization, but the company's negative profit margin of -663.4% highlights its current reliance on external funding. Key risks include clinical trial failures, regulatory hurdles, and the need for additional capital. The company's low beta of 0.14 indicates lower volatility compared to the broader market, but this does not mitigate the inherent risks associated with biotechnology investments. The company's market capitalization is $29.7M as of 2026-05-10.

Based on FMP financials and quantitative analysis

ALLK Key Highlights

Lirentelimab (AK002) is in Phase III study for eosinophilic gastritis and/or eosinophilic duodenitis.

• Lirentelimab (AK002) is in Phase II/III study for eosinophilic esophagitis.
• Gross Margin of 50.0% indicates potential profitability upon commercialization.
• Market Cap of $29.7M as of 2026-05-10 reflects its current valuation.
• Profit Margin of -663.4% highlights reliance on external funding.

Who Are ALLK's Competitors?

ALLK is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are ALLK's Key Strengths?

Lead product lirentelimab (AK002) in Phase III trials.

• Focus on unmet medical needs in allergy and inflammatory diseases.
• Proprietary technology targeting immunomodulatory receptors.
• Experienced management team in drug development.

What Are ALLK's Weaknesses?

Clinical-stage company with no approved products.

• High reliance on the success of lirentelimab.
• Negative profit margin and reliance on external funding.
• Limited financial resources compared to larger pharmaceutical companies.

What Could Drive ALLK Stock Higher?

Data readout from Phase III study of lirentelimab for eosinophilic gastritis/duodenitis.

• Data readout from Phase II/III study of lirentelimab for eosinophilic esophagitis.
• Enrollment and progress in Phase II clinical study of lirentelimab for atopic dermatitis and chronic spontaneous urticaria.
• Development and advancement of AK006 for allergic and inflammatory diseases.

What Are the Key Risks for ALLK?

Financial-distress signal — its Altman Z-Score of -29.64 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-38.4%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures or delays for lirentelimab and AK006.
• Regulatory hurdles and delays in obtaining FDA approval.
• Competition from other companies developing similar therapies.
• Dependence on external funding to support clinical development.
• Patent challenges and intellectual property disputes.

What Are the Growth Opportunities for ALLK?

• Expansion into Atopic Dermatitis and Chronic Spontaneous Urticaria: Allakos is currently conducting a Phase II clinical study of lirentelimab for atopic dermatitis and chronic spontaneous urticaria. Positive results could open up a significant market opportunity, as these conditions affect millions worldwide. The atopic dermatitis market is projected to reach $16.4 billion by 2027, while the chronic spontaneous urticaria market is expected to reach $3.7 billion by 2028. Successful trials and subsequent commercialization could significantly increase Allakos's revenue streams.
• Development of AK006 for Allergic and Inflammatory Diseases: Allakos is developing AK006 to treat allergic and inflammatory diseases, expanding its pipeline beyond lirentelimab. The market for allergic and inflammatory disease treatments is substantial and growing, driven by increasing prevalence and unmet medical needs. Successful development and commercialization of AK006 could diversify Allakos's product portfolio and reduce its reliance on lirentelimab. The global inflammatory disease market is projected to reach $127.7 billion by 2028.
• Treatment of Mast Cell Gastrointestinal Disease: Allakos is exploring the potential of lirentelimab for treating mast cell gastrointestinal disease. This represents a significant growth opportunity, as there are limited treatment options available for these conditions. Successful development and commercialization of lirentelimab for mast cell gastrointestinal disease could establish Allakos as a leader in this niche market. The market size for mast cell disorders is expected to grow as diagnostic capabilities improve and awareness increases.
• Treatment of Severe Allergic Conjunctivitis: Allakos is developing lirentelimab for the treatment of severe allergic conjunctivitis. This condition affects a significant portion of the population and can significantly impact quality of life. The allergic conjunctivitis market is expected to grow, driven by increasing prevalence and the development of new therapies. Successful development and commercialization of lirentelimab for severe allergic conjunctivitis could provide Allakos with a valuable revenue stream. The global allergic conjunctivitis market is projected to reach $3.1 billion by 2027.
• Treatment of Indolent Systemic Mastocytosis: Allakos is also exploring the potential of lirentelimab for the treatment of indolent systemic mastocytosis. This rare disease represents an unmet medical need, and successful development and commercialization of lirentelimab could provide Allakos with a first-in-class therapy. The market for indolent systemic mastocytosis is expected to grow as diagnostic capabilities improve and awareness increases. While the market size is relatively small, the potential for orphan drug designation and premium pricing could make this a valuable opportunity for Allakos.

What Are ALLK's Competitive Advantages?

• Patented lirentelimab (AK002) provides exclusivity.
• Clinical trial data demonstrating efficacy and safety.
• Focus on specific immunomodulatory receptors.
• Expertise in developing monoclonal antibody therapeutics.

What Does ALLK Do?

Allakos Inc., incorporated in 2012 and headquartered in Redwood City, California, is a clinical-stage biopharmaceutical company dedicated to developing therapeutics that target immunomodulatory receptors present on immune effector cells. These therapeutics aim to address allergy, inflammatory, and proliferative diseases. The company's primary focus is on its lead monoclonal antibody, lirentelimab (AK002), which is designed to inhibit Siglec-8, an inhibitory receptor selectively expressed on eosinophils and mast cells. Lirentelimab is currently undergoing several clinical trials. These include a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis, a Phase II/III study for eosinophilic esophagitis, and a Phase II clinical study for atopic dermatitis and chronic spontaneous urticaria. Allakos is also exploring the potential of lirentelimab for treating mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis. In addition to lirentelimab, Allakos is developing AK006 to treat allergic and inflammatory diseases, further expanding its therapeutic pipeline. The company operates with a team of 131 employees, managing the development and clinical trials of its therapeutic candidates.

What Products and Services Does ALLK Offer?

• Develops therapeutics targeting immunomodulatory receptors.
• Focuses on treatments for allergy, inflammatory, and proliferative diseases.
• Lead product is lirentelimab (AK002), a monoclonal antibody.
• Conducts clinical trials for eosinophilic gastritis/duodenitis, eosinophilic esophagitis, atopic dermatitis, and chronic spontaneous urticaria.
• Develops AK006 for allergic and inflammatory diseases.
• Explores treatments for mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis.

How Does ALLK Make Money?

• Develops and patents novel therapeutic antibodies.
• Conducts preclinical and clinical trials to evaluate safety and efficacy.
• Seeks regulatory approval from agencies like the FDA.
• Aims to commercialize approved therapies through partnerships or direct sales.

What Industry Does ALLK Operate In?

Allakos operates within the biotechnology industry, a sector characterized by high research and development costs, lengthy regulatory approval processes, and significant market potential for successful therapies. The company focuses on developing treatments for allergy, inflammatory, and proliferative diseases, addressing a market with substantial unmet needs. Competition includes established pharmaceutical companies and other biotechnology firms developing similar therapies. The success of Allakos depends on its ability to navigate the complex regulatory landscape and demonstrate the efficacy and safety of its drug candidates in clinical trials. The biotechnology industry is experiencing growth driven by advancements in genomics, proteomics, and personalized medicine.

Who Are ALLK's Key Customers?

• Patients suffering from eosinophilic gastritis/duodenitis.
• Patients suffering from eosinophilic esophagitis.
• Patients suffering from atopic dermatitis.
• Patients suffering from chronic spontaneous urticaria.

The most recent 12 insider filings for Allakos Inc. break down as 12 sales and 0 purchases. On net that is roughly 6.2M shares disposed (about $12.8M), a signal worth weighing alongside the fundamentals.

Wall Street analysts project Allakos Inc. revenue of about $0 for fiscal 2026, with EPS near $-0.33.

Allakos Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -29.64 places it in the distress zone, a signal of elevated financial risk.

Return on equity for Allakos Inc. stands at -38.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -43.3%, showing how much profit it generates from its asset base. A current ratio of 14.23 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -87.2%, the inverse of the P/E and a quick read on earnings relative to price.

Allakos Inc. (ALLK) Valuation Context

Valued at $29.7M, ALLK is classified as a micro-cap stock.

Company Profile

Allakos Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in San Carlos, US. The company is led by CEO Robert Alexander. ALLK has traded publicly since 2018.

ALLK Financials

ALLK Latest News

Common Questions About ALLK (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources